Navigation Links
Genmab Announces Results for the First Nine Months of 2007
Date:10/30/2007

owards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted,

Sr. Director,

Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com '/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, more ... In the military, burn injury is a ubiquitous ... care. More than 800 service members sustained burn ... slowly, remain inflamed and often become infected, producing ... functionally damaging. While developments in supportive care have ...
(Date:9/29/2014)... Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian ... three Promissory Note holders, two of whom are the ... July 2014 for a total of $ 300,000 opted ... 3,500,001 restricted common shares. Notes were repayable within one ... the coupon were convertible into common shares to be ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2
... This release is available in German . ... in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together ... (TUM), have now presented a novel molecular switch in the ... the switch is the position of a single proton in ...
... COLUMBUS, Ohio, Dec. 12, 2011   Chemical Abstracts ... Chemical Society and the world,s authority for chemical ... InfoChem, GmbH (InfoChem), a  leader ... as datamining in chemical science documents, headquartered in ...
... Zyngenia , Inc ... antibody-based drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as ... our start in September 2009, Zyngenia has made tremendous progress in ...
Cached Biology Technology:The smallest conceivable switch 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3
(Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
(Date:9/29/2014)... considered capable of doing anything on their own. But ... water. In the future, such moving droplets may deliver ... to be self-moving is a feature normally ... be self-moving, report researchers from University of Southern Denmark ... , The researchers have made alcohol droplets move in ...
(Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... a telescope promise to make it easier for people ... requiring sharper distance vision. Schepens Eye Research Institute scientists ... devices in an article published in the May/June issue ... in print form to subscribers this month. ...
... A new study by researchers from Columbia University,s ... most challenging issues in infant health and preventing mother-to-child ... HIV-infected mothers had been advised that for the best ... by a rapid weaning four to six months after ...
... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... immune response modifier with potent antiviral and antitumor activity, ... (OGFr) axis for its action. This discovery, reported ... and Medicine , provides new insights into a widely ...
Cached Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
pH-insensitive fluorescence (pH 2-12)...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: